AAP
PFE icon

Aristotle Atlantic Partners’s Pfizer PFE Stock Holding History

Aristotle Atlantic Partners’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,822
Closed -$114K – 101
2019
Q1 		$114K Buy
+2,822
New +$113K 0.03% 89
2018
Q1 		– Sell
-110,046
Closed -$3.78M – 95
2017
Q4 		$3.78M Buy
+110,046
New +$3.75M 1.36% 18

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Aristotle Atlantic Partners's PFE Position: Q2 2019 in Review

Aristotle Atlantic Partners sold out of Pfizer (PFE) in Q2 2019, closing a stake of 2,822 shares — an estimated $114K sold.

Aristotle Atlantic Partners first reported a position in PFE in Q4 2017 and held it in 2 quarters. The position peaked at $3.78M in Q4 2017. 2,378 funds tracked by Wall St. Rank hold PFE as of Q2 2019.

  • Aristotle Atlantic Partners reported no remaining Pfizer position as of Q2 2019 after selling out during the quarter.
  • Aristotle Atlantic Partners sold 2,822 Pfizer shares in Q2 2019, an estimated $114K.
  • Aristotle Atlantic Partners first reported a position in Pfizer in Q4 2017 and held it in 2 quarters.
  • Aristotle Atlantic Partners's Pfizer position peaked at $3.78M in Q4 2017.
  • 2,378 funds tracked by Wall St. Rank held Pfizer as of Q2 2019.

Based on Aristotle Atlantic Partners's 13F filing for Q2 2019, filed 13 Aug 2019.